STX-721 shows efficacy and selectivity in EGFR exon 20 mutant models
Nov. 9, 2022
Researchers from Scorpion Therapeutics Inc. presented preclinical data for the novel EGFR exon 20 mutant inhibitor STX-721, being developed for the treatment of non-small-cell lung cancer (NSCLC).
